Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association

Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Kee Hyung, Jang, Jae-Won, Suh, Jeewon, Yi, SangHak, Bae, Jae-Sung, Lim, Jae-Sung, Lee, Hyon, Chin, Juhee, Park, Young Ho, Hong, Yun Jeong, Kim, Geon Ha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Dementia Association 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085535/
https://www.ncbi.nlm.nih.gov/pubmed/35585909
http://dx.doi.org/10.12779/dnd.2022.21.2.45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085535/
https://www.ncbi.nlm.nih.gov/pubmed/35585909
http://dx.doi.org/10.12779/dnd.2022.21.2.45

Ejemplares similares